| Disease | A TWO-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED PROSPECTIVE TRIAL TO INVESTIGATE THE EFFECT OF A COMMERICAL GARLIC POWDER PREPARATION (KWAI 900 MG PER DAY) ON SERUM LIPIDS, LIPOPROTEINS, BLOOD PRESSURE AND HEART RATE
OVER PATIENTS. AFTER A LEAD-IN PHASE (AT LEAST 8 MONTHS) WITH A STANDARDIZED NATIONAL CHOLESTEROL EDUCATION PROGRAM STEP I DIET PROVEN BY FOOD RECORDS, 50 PATIENTS WERE RANDOMIZED EITHER TO GARLIC (N = 28) OR PLACEBO TREATMENT (N = 22).
BEFORE AND AFTER 12 WEEKS OF TREATMENT TOTAL CHOLESTEROL, LDL CHOLESTEROL, HDL CHOLESTEROL, TRIGLYCERIDES, LIPOPROTEIN (A), APOLIPROTEINS B AND A-I, SYSTOLIC AND DIASTOLIC BLOOD PRESSURE, HEART RATE AND BODY MASS INDEX WERE MEASURED. NEITHER
IN THE PLACEBO NOR IN THE GARLIC GROUP COULD ANY SIGNIFICANT WITHIN-GROUP CHANGES BE OBSERVED FOR ALL PARAMETERS EXCEPT DIASTOLIC BLOOD PRESSURE. NO TRENDS IN ANY PARTICULAR DIRECTION WERE DETECTED.
A COMMERCIAL PRODUCT, KWAI, WAS USED. |